Search results
Results from the WOW.Com Content Network
Novavax successfully developed a COVID-19 vaccine that is currently its only product on the market. The company has been working on two other candidates. One is an investigational influenza vaccine.
Kennedy has long railed against vaccines, once calling those that protect against Covid-19 a "crime against humanity." He has treaded more carefully in recent weeks, though, and has said he wouldn ...
Shares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday ...
An hour before the market closed Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6%, and Pfizer fell almost 2%.
Like a fad that arrived and left, Covid-19 vaccine stocks are out of favor now. Novavax (NASDAQ:NVAX) is facing tremendous selling pressure compared to its peers. Unlike its competitors that ...
The news got even better last week, when the UK drug regulatory commission MHRA authorized Pfizer and BioNTech to distribute their Covid-19 mRNA vaccine for emergency use and the first doses could ...
The company — which expects its 2023 revenus to be at least $6 billion — reported $1.8 billion in COVID-19 vaccine sales in the third quarter and $3.9 billion through Q3.
Stocks of coronavirus vaccine could run out at the end of January unless new ones such as the Oxford jab are approved, a former minister has warned. Former health secretary Jeremy Hunt told the ...